OR WAIT null SECS
A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.
While the American Heart Association Scientific Sessions 2020 was filled with noteworthy studies, a pair of phase 3 trials examining sotagliflozin in patients with type 2 diabetes may be the most impactful. Presented during a late-breaking session, the SCORED and SOLOIST trials demonstrated the effects of the dual SGLT1/SGLT2 inhibitor in patients with chronic kidney disease and worsening heart failure.
Despite both trials being cut short due to a lack of funding during the COVID-19 pandemic, results from both trials left many impressed and carry multiple implications for clinic practice. While the results have implications for sotagliflozin, which results indicate could lower the risk of stroke, they also offer further insight into the effects of the SGLT2 inhibitor class.
For further perspective on the trials, check out this video with Muthiah Vaduganathan, MD, MPH, a cardiologist at Brigham and Women’s Hospital, titled: “4 Takeaways from SOLOIST & SCORED”.
Check out our coverage of the phase 3 data from sotagliflozin and hear more from study chair Deepak Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, in an interview with Practical Cardiology.